Alumis (ALMS) Competitors $9.64 -0.71 (-6.86%) (As of 11/20/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsTrends ALMS vs. RXRX, TARS, IRON, GLPG, XNCR, IMCR, NRIX, ARVN, KNSA, and NTLAShould you be buying Alumis stock or one of its competitors? The main competitors of Alumis include Recursion Pharmaceuticals (RXRX), Tarsus Pharmaceuticals (TARS), Disc Medicine (IRON), Galapagos (GLPG), Xencor (XNCR), Immunocore (IMCR), Nurix Therapeutics (NRIX), Arvinas (ARVN), Kiniksa Pharmaceuticals (KNSA), and Intellia Therapeutics (NTLA). These companies are all part of the "pharmaceutical products" industry. Alumis vs. Recursion Pharmaceuticals Tarsus Pharmaceuticals Disc Medicine Galapagos Xencor Immunocore Nurix Therapeutics Arvinas Kiniksa Pharmaceuticals Intellia Therapeutics Recursion Pharmaceuticals (NASDAQ:RXRX) and Alumis (NASDAQ:ALMS) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, earnings, valuation, risk, institutional ownership, dividends, analyst recommendations, community ranking and media sentiment. Do institutionals and insiders believe in RXRX or ALMS? 89.1% of Recursion Pharmaceuticals shares are owned by institutional investors. 15.8% of Recursion Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Do analysts prefer RXRX or ALMS? Recursion Pharmaceuticals presently has a consensus target price of $9.25, indicating a potential upside of 53.15%. Alumis has a consensus target price of $26.83, indicating a potential upside of 178.35%. Given Alumis' stronger consensus rating and higher possible upside, analysts clearly believe Alumis is more favorable than Recursion Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Recursion Pharmaceuticals 0 Sell rating(s) 3 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.40Alumis 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 2 Strong Buy rating(s) 3.25 Does the MarketBeat Community prefer RXRX or ALMS? Recursion Pharmaceuticals received 16 more outperform votes than Alumis when rated by MarketBeat users. However, 100.00% of users gave Alumis an outperform vote while only 55.10% of users gave Recursion Pharmaceuticals an outperform vote. CompanyUnderperformOutperformRecursion PharmaceuticalsOutperform Votes2755.10% Underperform Votes2244.90% AlumisOutperform Votes11100.00% Underperform VotesNo Votes Which has preferable valuation and earnings, RXRX or ALMS? Alumis has lower revenue, but higher earnings than Recursion Pharmaceuticals. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRecursion Pharmaceuticals$44.58M38.84-$328.07M-$1.53-3.95AlumisN/AN/AN/AN/AN/A Is RXRX or ALMS more profitable? Alumis has a net margin of 0.00% compared to Recursion Pharmaceuticals' net margin of -579.52%. Alumis' return on equity of 0.00% beat Recursion Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Recursion Pharmaceuticals-579.52% -76.56% -55.68% Alumis N/A N/A N/A Does the media refer more to RXRX or ALMS? In the previous week, Alumis had 13 more articles in the media than Recursion Pharmaceuticals. MarketBeat recorded 24 mentions for Alumis and 11 mentions for Recursion Pharmaceuticals. Recursion Pharmaceuticals' average media sentiment score of 0.13 beat Alumis' score of -0.08 indicating that Recursion Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Recursion Pharmaceuticals 3 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Alumis 3 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 3 Negative mention(s) 2 Very Negative mention(s) Neutral SummaryAlumis beats Recursion Pharmaceuticals on 9 of the 14 factors compared between the two stocks. Ad Porter & CompanyElection warning coming true… If you missed it, my emergency election broadcast is now available - watch it before it's too late.Click here to watch it now. Get Alumis News Delivered to You Automatically Sign up to receive the latest news and ratings for ALMS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ALMS vs. The Competition Export to ExcelMetricAlumisPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$455.22M$6.44B$5.05B$8.82BDividend YieldN/A8.11%5.17%4.07%P/E RatioN/A10.69125.6917.78Price / SalesN/A243.731,179.7874.25Price / CashN/A22.1633.7732.53Price / BookN/A5.474.684.68Net IncomeN/A$153.61M$119.54M$226.08M7 Day Performance-10.82%-4.32%-2.46%-2.04%1 Month Performance-19.87%-8.61%-4.08%0.06%1 Year PerformanceN/A28.79%29.82%24.60% Alumis Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ALMSAlumisN/A$9.64-6.9%$26.83+178.4%N/A$455.22MN/A0.00N/AAnalyst RevisionRXRXRecursion Pharmaceuticals1.9971 of 5 stars$6.04-3.7%$9.25+53.1%-12.0%$1.80B$44.58M0.00400Analyst ForecastOptions VolumeHigh Trading VolumeTARSTarsus Pharmaceuticals1.8691 of 5 stars$46.58-0.7%$54.20+16.4%+166.2%$1.79B$17.45M-12.2350Analyst RevisionIRONDisc Medicine3.1622 of 5 stars$62.55+5.0%$85.80+37.2%+22.4%$1.77BN/A0.0078Insider TradeAnalyst RevisionGLPGGalapagos1.2816 of 5 stars$25.64-3.9%$30.75+19.9%-31.4%$1.76B$259.40M0.001,123Analyst DowngradeShort Interest ↓Gap DownXNCRXencor3.5459 of 5 stars$23.72+0.4%$35.75+50.7%+19.3%$1.65B$168.34M0.00280IMCRImmunocore2.9958 of 5 stars$32.42-0.4%$69.18+113.4%-28.7%$1.63B$249.43M0.00497Positive NewsNRIXNurix Therapeutics2.5454 of 5 stars$22.64-0.7%$29.40+29.9%+247.8%$1.61B$76.99M0.00300ARVNArvinas3.0807 of 5 stars$22.69+4.9%$61.08+169.2%+4.2%$1.56B$78.50M-4.86445Analyst ForecastShort Interest ↓KNSAKiniksa Pharmaceuticals1.9939 of 5 stars$21.21+1.9%$36.60+72.6%+33.9%$1.50B$270.26M0.00220NTLAIntellia Therapeutics4.5389 of 5 stars$13.12-7.1%$54.94+318.7%-56.7%$1.44B$36.28M0.00600Analyst Forecast Related Companies and Tools Related Companies RXRX Alternatives TARS Alternatives IRON Alternatives GLPG Alternatives XNCR Alternatives IMCR Alternatives NRIX Alternatives ARVN Alternatives KNSA Alternatives NTLA Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ALMS) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored24/7 Automated Profits in CryptoThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | SponsoredBut another coin could soar even higher …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin co...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alumis Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Alumis With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
